Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00060489

Enrollment

Unknown

Registered

2003-05-08

Start date

2002-09-30

Completion date

2003-09-30

Last updated

2011-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar Disorder, Depression, Bipolar

Keywords

Bipolar Depression

Brief summary

The purpose of this study is to evaluate the efficacy and safety of quetiapine in the treatment of a major depressive episode in patients with bipolar disorder.

Interventions

DRUGSEROQUEL (quetiapine fumarate) Tablets

Study design

Primary purpose

TREATMENT

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Written Informed Consent; * Bipolar disorder with most recent episode depressed; * Outpatient status

Exclusion criteria

* Patients with a current Axis I disorder other than bipolar disorder within 6 months of screening; * Patients whose current episode of depression exceeds 12 months or is less than 4 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 3, 2026